Page 16 | Certara

Case Study

How Model-informed drug development rescue projects from a risky situation

Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…

CertaraJune 26, 2025

Press Coverage

Increasing Productivity In Pharma R&D Starts With Data

This article discusses the growing volume of raw data collected during clinical research, and how…

CertaraJune 25, 2025

Blog

FDA ESG NextGen for Regulatory Submissions

The FDA ESG NextGen for Regulatory Submissions has replaced the FDA’s WebTrader and simplifies pharmaceutical…

CertaraJune 25, 2025

Poster

Applications of an Immunogenicity QSP Platform: Predictive Modelling for ADA and PK Impact for Biotherapeutic Combinations

Learn how a QSP platform predicts ADA and PK effects in combo immunotherapies like nivolumab…

CertaraJune 23, 2025

Announcement

Certara Enhances Integral Data Repository with Powerful REST API Capabilities in Version 25.4.1

Radnor, PA – June 20, 2025 - Certara, Inc. (Nasdaq: CERT), a global leader in…

Danielle PillsburyJune 20, 2025

Publication

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully…

Danielle PillsburyJune 19, 2025

Poster

QSP Modeling in Cancer Therapy | Advancing Tumor-Selective Treatments

Discover how Certara uses QSP modeling to advance the development of KK2269, a bispecific antibody…

CertaraJune 18, 2025

On-Demand Webinar

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…

CertaraJune 18, 2025

Press Coverage

How is the pharmaceutical industry addressing global health inequities?

Explore Karen Rowland Yeo's insights on using Model-Informed Drug Development to address global health equities…

CertaraJune 17, 2025

Poster

A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3

Explore a cutting-edge minimal PBPK/PD oncology mouse model for 212Pb-based Radio-DARPin MP0712, meticulously designed to…

CertaraJune 16, 2025

How Model-informed drug development rescue projects from a risky situation

Increasing Productivity In Pharma R&D Starts With Data

FDA ESG NextGen for Regulatory Submissions

Applications of an Immunogenicity QSP Platform: Predictive Modelling for ADA and PK Impact for Biotherapeutic Combinations

Certara Enhances Integral Data Repository with Powerful REST API Capabilities in Version 25.4.1

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

QSP Modeling in Cancer Therapy | Advancing Tumor-Selective Treatments

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

How is the pharmaceutical industry addressing global health inequities?

A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3

Newsletter sign up

Quick links

Solutions

Contact